Two years ago, the World Health Organization (WHO) declared COVID-19 a “pandemic.” We look back at key activities from BIO and the biopharmaceutical industry—and where we go from here.

What will it take to end the pandemic? A true return to normalcy includes international travel and the movement of people globally. But how do we do this safely? How do we get vaccines to poorer areas of the world? As BIO CEO Dr. Michelle McMurry-Heath says in the latest episode of I am BIO, …

This week is “Made in America Week.” According to the president, this is a time to pay special tribute to U.S. innovators, builders, entrepreneurs, and “all those who work with their hands every day to make America great.” We certainly have a lot to celebrate! As Under Secretary of Commerce for…

With the 40th anniversary of the Bayh-Dole Act this year, BIO connected with Senator Thom Tillis (R-NC), Chairman of the Senate Subcommittee on Intellectual Property, for a discussion about the importance of intellectual property and innovation. BIO: This year is the 40th anniversary of the Bayh…

The Subcommittee on Consumer Protection and Commerce of the Committee on Energy and Commerce is set to examine the U.S. patent system this morning. Ahead of the hearing – and in honor of #ThrowBackThursay – we are resurfacing a piece by BIO’s Tom DiLenge that helps debunk some of the most…

As the debate on drug pricing continues, our elected leaders will almost certainly adopt policies that will significantly impact—for better or for worse—the lives of many patients. With that in mind, how we do we ensure patients are at the center of this discussion? It starts by recognizing some…

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property, recently testified at the second of three hearings in the Intellectual Property Subcommittee of the Senate Judiciary Committee on the subject of “The State of Patent Eligibility in America.” The hearings are looking at Section 101…

A new report from BIO and AUTM demonstrates to enormous return on investment that ultimately comes from public funding of early-stage basic research. The licensing of this research has significantly expanded US gross domestic product, industrial gross output, and jobs over the last 22 years.  …

In a recent piece for The Washington Post, author Christopher Rowland inaccurately suggested that the federal government has the power to effectively impose price controls over products that have a link to federally-funded research through its patent “march-in” rights under the Bayh-Dole…

Dr. Gregory Dolin of the Center for Medicine and Law at the University of Baltimore School of Law shared his objections to legislative proposals that falsely link drug costs with patents in an op-ed that ran in The Washington Times this week. As Dolin states, current legislative proposals would…